The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients
The Pershing Square Foundation announced a $6 million Lotus Award to fund eight leading scientists tackling ovarian‑cancer, the deadliest yet under‑funded gynecologic disease. The second‑year initiative builds on a decade of work through the Pershing Square Sohn Cancer Research Alliance, emphasizing early detection, immunotherapy, and metabolic targets. Awardees span Columbia, Duke, Johns Hopkins and other top institutions, pursuing approaches from CAR‑T cells to engineered probiotics. The effort aims to accelerate breakthroughs and raise awareness for a disease that claims thousands of lives annually.
Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides...
Mountain Valley MD reported progress on its patented Quicksome™ sublingual delivery platform, completing initial formulation work on several high‑interest peptides such as BPC‑157, GHK‑Cu, KPV, SNAP‑8 and retatrutide. The six‑month effort expanded the company’s lab capabilities and demonstrated stability and...
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of Its Entire DNA Solid Tumor Portfolio
Tempus AI announced that the FDA has approved its xT CDx next‑generation sequencing platform for a tumor‑only indication, making it the first lab to hold companion diagnostic clearance for both tumor‑only and tumor‑normal comprehensive genomic profiling. The 648‑gene assay can now...
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NeuroPace received FDA clearance for ECoG Assistant™, its first AI‑driven clinician‑enabled feature for the RNS System. The tool leverages a proprietary dataset of 124,450 epileptologist‑labeled intracranial EEG records to flag ECoGs of interest and present trends in a single view....
Seven-Year Analysis From Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer reported seven‑year follow‑up from the Phase 3 CROWN trial, showing that lorlatinib (LORBRENA) achieved a 55% progression‑free survival (PFS) rate versus just 3% for crizotinib (XALKORI). Median PFS was not reached for LORBRENA, translating to an 81% reduction in risk...
FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital
Coredio’s Cardiac Performance Simulation Engine (CPSE™) received FDA Breakthrough Device Designation and entry into the Total Product Life Cycle Advisory Program, accelerating its path to a 510(k) clearance. The SaMD platform translates data from consumer smartwatches and standard blood‑pressure cuffs...
EClinicalWorks AI-Powered EHR Strengthens Access to Care and Operational Efficiency at Rural Tennessee Clinic
Medical Specialty Clinic in rural Tennessee adopted eClinicalWorks' AI‑powered EHR suite to boost patient access and streamline operations across in‑person, telehealth, and home visits. AI tools such as Sunoh.ai, PRISMA, and healow Genie cut documentation time, while integrated billing and...
Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset...
Beren Therapeutics announced that the FDA has extended the review period for its New Drug Application for adrabetadex, a cyclodextrin‑based therapy for infantile‑onset Niemann‑Pick disease type C, by three months. The new PDUFA target action date is November 17, 2026, following a major...
Athenahealth, Aetna CVS Health, and Catalyst Health Group Recognized for Advancing Real-Time Clinical Data Exchange
athenahealth, Aetna CVS Health, and Catalyst Health Group earned the 2026 KLAS Points of Light and K2 Collaborative Peak awards for a joint effort to enable real‑time clinical data exchange between payer and provider systems. The collaboration leverages HL7 FHIR...
WellSky® Unifies AI and the Patient Record in New Point of Care App for Home Health Clinicians
WellSky launched a mobile‑first Point of Care app for home‑health clinicians that embeds AI‑driven insights throughout the entire visit. The app pulls the complete patient record from the WellSky Home Health platform, enabling real‑time, context‑rich assistance on clinicians' phones or...
AI Meets Olfaction: SpotitEarly Unveils LUCID 2.0, Scaling Early Cancer Detection to Millions
SpotitEarly introduced LUCID 2.0, a bio‑AI hybrid platform that pairs trained detection dogs with a multi‑modal sensor array and deep‑learning algorithms to deliver breath‑based cancer screening at clinical scale. The system can process up to 1.73 million tests per year per center...
Medix Launches Executive Search Practice Focused on Revenue Cycle Leadership
Medix announced a new executive‑search practice dedicated to senior revenue‑cycle leadership roles in healthcare. The service uses a retained, commitment‑based model that prioritizes exclusive, high‑touch engagements. By proactively mapping passive talent, Medix aims to fill critical positions that are hard...
Virchow Medical Strengthens Scientific Advisory Board with New Appointments
Virchow Medical announced that Dr. William Morice, CEO of Mayo Clinic Laboratories, has joined its Scientific Advisory Board, and that Khosrow Shotorbani, founder of Clinical Lab 2.0, has moved from the Market Outreach board to the SAB. The company also held...
ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection
ClearNote Health announced a $52 million Series D financing round, bringing its total capital to over $185 million. The company also appointed Kevin Keegan, a veteran of Illumina, BD and Hologic, as President and COO. Proceeds will fund commercial expansion, clinical studies, and further...
Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting
Junevity will present pioneering in‑vivo data showing an siRNA therapeutic can restore global gene networks to a healthier state. Co‑founder Dr. Janine Sengstack will share results from diabetic mouse studies and safety data in rats and non‑human primates, marking the...
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across Its Joint Reconstruction Portfolio
DePuy Synthes announced a definitive agreement to acquire selective rights to MinMaxMedical’s Gemtrack miniature radio‑frequency (RF) tracking technology for its joint reconstruction portfolio. The RF tracker will be integrated into the VELYS digital surgery platform, covering shoulder, hip and knee procedures...
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure
ViaLase, Inc. has begun the global commercial rollout of its FLIGHT procedure, the first femtosecond laser‑guided, incision‑free trabeculotomy for open‑angle glaucoma. The inaugural treatments were performed at Centre for Sight in London and Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf...
Unio Health Partners and Thesis Care Announce Partnership to Scale AI-Powered Clinical Teams Across Specialty Care
Unio Health Partners, California's largest multi‑specialty physician platform, has partnered with AI‑driven care team provider Thesis Care to embed multiple AI agents across its urology, gastroenterology and radiation oncology practices. The collaboration will automate high‑volume tasks such as care‑gap closure,...
Inocras Announces ASCO 2026 Online Publication: Whole-Genome HRD Phenotyping as a Predictor of PARP Inhibitor Benefit in First-Line Maintenance High-Grade...
Inocras announced that whole‑genome sequencing‑based HRD phenotyping predicts benefit from PARP inhibitor maintenance in high‑grade serous ovarian cancer. In a real‑world study of 84 patients at Severance Hospital, HRD‑positive tumors had a median progression‑free survival of 27.5 months versus 12.0...
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
Galderma announced that the U.S. FDA has approved Differin Epiduo® Acne Gel for over‑the‑counter sale to consumers aged 12 and older. The switch moves a prescription‑strength combination of adapalene 0.1% and benzoyl peroxide 2.5% into the retail market, leveraging more than...
Zelis Recognized as a 2026 Great Place to Work® in the U.S. and India
Zelis was certified as a Great Place to Work® in both the United States and India, marking a fourth consecutive U.S. award and a third in India. The certification reflects feedback from more than 3,000 associates, with 85% rating the...
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (Mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat) to treat anaemia in adults with transfusion‑dependent or non‑transfusion‑dependent alpha‑ or beta‑thalassaemia. The approval follows positive CHMP opinion and data from the Phase 3 ENERGIZE and ENERGIZE‑T...
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
PharmaEssentia will unveil new Phase 3 SURPASS‑ET data at ASCO and EHA 2026, highlighting that early initiation of ropeginterferon alfa‑2b yields markedly higher two‑year progression‑free survival (76.9% vs 43.1%) in high‑risk essential thrombocythemia (ET). Integrated analyses of SURPASS‑ET and Phase 2b EXCEED‑ET,...
Hyperfine Announces Presentation of Results From the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
Hyperfine presented PRIME study results at the SAEM 2026 meeting, showing its AI‑powered Swoop® portable MRI dramatically shortens imaging time in emergency departments. In a randomized trial of 100 patients, bedside MRI began scans in a median 1.28 hours versus 7.76 hours...
BioVigil Appoints Brad Ryba as Chief Technology Officer to Accelerate Innovation and Market Expansion
BioVigil has appointed Brad Ryba as chief technology officer to steer its technology and data strategy. Ryba brings more than 25 years of leadership across SaaS, healthcare, telecom and e‑commerce, positioning the firm to enhance platform interoperability and scale. BioVigil’s...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Scribe Therapeutics received clearance from Australia’s TGA to start a first‑in‑human Phase 1 study of STX‑1150, an in‑vivo CRISPR‑based therapy that epigenetically silences PCSK9 to lower LDL‑C. The open‑label, single‑ascending‑dose trial will enroll up to 64 high‑risk hypercholesterolemia patients across Australia...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Merck has dosed the first patient in the Phase 3 PROCEADE‑CRC‑03 trial of Precem‑TcT, the company’s inaugural anti‑CEACAM5 antibody‑drug conjugate (ADC) featuring an exatecan payload for metastatic colorectal cancer (mCRC). In Phase 1, the ADC achieved a 20.7% confirmed objective response rate...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Bayer announced that it will unveil 16 new oncology abstracts at the ASCO 2026 meeting in Chicago, spanning prostate, breast, lung, renal‑cell, colorectal and salivary‑gland cancers. The headline presentation will feature Phase II head‑to‑head data comparing NUBEQA (darolutamide) with enzalutamide in...
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
Ontada, McKesson’s oncology data unit, has integrated Florida Cancer Specialists & Research Institute (FCS) data into its real‑world evidence platform. The addition brings information from more than 530 community oncology providers, including 270,000 extra oral prescriptions covering over 4,000 unique...
Fujifilm and mTuitive Link Structured Pathology Reporting to Enterprise Imaging in New Partnership
Fujifilm Healthcare Americas and mTuitive have launched a partnership that links mTuitive’s CAP‑compliant synoptic pathology reporting platform directly to Fujifilm’s Synapse Pathology PACS. The integration streams structured pathology data—including biomarker and cancer registry fields—through the laboratory information system into the...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
Leading NCI-Designated Cancer Centers Across the Country Leverage ConcertAI’s CancerLinQ to Support Personalized, Evidence-Based Quality Care
ConcertAI announced that the University of Rochester Medicine Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center have joined its CancerLinQ network. The addition expands the platform’s real‑world evidence reach to over 900 sites across all 50 states. CancerLinQ’s...
The Foundation for the National Institutes of Health Announces Recipients of the Deeda Blair Research Initiative for Disorders of the...
The Foundation for the National Institutes of Health announced three new awardees of the Deeda Blair Research Initiative for Disorders of the Brain. Each will receive $200,000 to fund innovative projects aimed at transforming diagnosis and treatment of severe mental...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte and Genesis Molecular AI have broadened their partnership, granting Genesis access to Incyte's proprietary experimental data to train the next‑generation GEMS AI platform. The deal includes a $120 million upfront payment—$80 million in cash and $40 million in equity—plus recurring research funding....
EndoQuest Advances Multicenter PARADIGM Trial with Completion of Procedures at Baylor St. Luke’s Medical Center
EndoQuest Robotics announced that Baylor St. Luke’s Medical Center has become an active site in its multicenter PARADIGM trial, successfully completing its first robotic endoscopic submucosal dissection (ESD) procedures using the Endoluminal Surgical (ELS) System. The trial, which evaluates safety and...
DNAnexus Scales AI-Driven Capabilities
DNAnexus unveiled a suite of AI‑driven tools that turn massive multi‑omic datasets into enterprise‑grade AI assets. The GenAI‑powered Omics Data Agent lets researchers query complex data with natural language, while the AutoML Assistant promises up to an 80% reduction in...
Nourish Raises $100M Series C to Reverse Chronic Disease with AI-Native Metabolic Clinic
Nourish, the nation’s largest dietitian‑led metabolic health clinic, announced a $100 million Series C round, lifting its total capital to $215 million. The funding, led by Menlo Ventures and joined by a slate of top venture firms, will expand its AI‑native clinic network,...
HOPPR Adds Mammography Narrative Model to Growing Vision-Language Model Library
HOPPR has introduced the EB 2D Mammo Narrative Model, a vision‑language model that converts 2D mammography images into structured JSON narratives. Trained on more than 200,000 mammogram studies from diverse U.S. sites, the model targets developers building AI‑assisted breast imaging tools rather...
Quantori and Knowledge3 Announce Co-Marketing Partnership to Advance Knowledge-Driven AI in Life Sciences
Quantori, a digital transformation firm for life sciences, announced a co‑marketing partnership with Knowledge3, a specialist in knowledge graphs and FAIR data. The alliance blends Quantori’s AI and scientific software expertise with Knowledge3’s knowledge‑first architecture to create scalable, context‑aware AI...
Dr. Reddy’s Laboratories Launches Its Generic Semaglutide Injection in Canada
Dr. Reddy’s Laboratories received Health Canada’s Notice of Compliance on April 28, 2026 and launched the first generic semaglutide injection in Canada, the inaugural G7 approval for a generic version of the GLP‑1 drug. The product is offered in 2 mg and 4 mg...
ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Two New Indications for Patients with HER2-Positive Early Breast Cancer
The FDA has approved AstraZeneca and Daiichi Sankyo’s ENHERTU (fam‑trastuzumab deruxtecan‑nxki) for both neoadjuvant and adjuvant treatment of HER2‑positive early‑stage breast cancer. In the neoadjuvant setting, ENHERTU plus taxane, trastuzumab and pertuzumab achieved a 67.3% pathologic complete response, outperforming standard...
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics received FDA clearance to begin the EXPRESS clinical trial of its UHeart xenotransplant, a pig‑derived heart with ten gene edits. The phase‑1/2/3 study will initially enroll up to two end‑stage heart‑failure patients, with safety and efficacy data reviewed...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Agenus published Phase 1b data on botensilimab plus balstilimab in 19 patients with treatment‑refractory hepatocellular carcinoma who had progressed after prior immunotherapy. The combination achieved a 17% objective response rate, a 50% clinical benefit rate at 18 weeks, median progression‑free survival...
Jamieson Wellness Inc. Announces Senior Credit Facilities Refinancing
Jamieson Wellness Inc. (TSX:JWEL) announced the amendment and restatement of its senior credit facilities, extending maturity to May 14 2031 and increasing revolving availability to $800 million CAD (≈$584 million USD). The agreement also adds an accordion feature that could raise the total borrowing...
Organon to Present New Research on Access and Value at ISPOR 2026
Organon (NYSE: OGN) will showcase eight peer‑reviewed abstracts at ISPOR 2026, the premier health‑economics conference in Philadelphia. The presentations span cost‑effectiveness and budget‑impact analyses for its women’s health implant NEXPLANON in Brazil, the atopic dermatitis cream VTAMA from a U.S. Medicaid...
“We Deserve the Same Rights as Other Health Care Workers:” PSW Day Protest at Doug Ford’s Office on May 19
Personal support workers (PSWs) represented by CUPE are protesting Ontario’s Health and Supportive Care Oversight Authority (HSCPOA), which they say lacks due‑process safeguards and representation. The union plans a rally outside Premier Doug Ford’s Etobicoke office on May 19, 2026, marking PSW Day....
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
Revvity, via its Immunodiagnostic Systems unit, secured FDA clearance for a Total Testosterone chemiluminescence immunoassay (ChLIA). The new assay joins FDA‑cleared free testosterone and SHBG tests, creating the only single‑platform, fully automated testosterone testing suite. The portfolio targets hypogonadism diagnosis...
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories and South Korean biotech MEDIPOST have signed a non‑exclusive memorandum of understanding to provide GMP‑compliant testing and regulatory support for MEDIPOST’s cell‑therapy pipeline. The collaboration will initially focus on the Asia‑Pacific and North American markets, with the...
Nursing Engagement Improves While Early-Career Nurse Departures Persist at Alarming Rates
Press Ganey’s State of Nursing 2026, based on more than 500,000 nurses and advanced practice providers, shows overall engagement beginning to stabilize but remaining fragile. Early‑career nurses are still leaving at a rate of one in five, while total RN turnover...